Contursi Terme

Last updated
Contursi Terme
Comune di Contursi Terme
Contursi Terme-Stemma.png
Location of Contursi Terme
Contursi Terme
Italy provincial location map 2016.svg
Red pog.svg
Contursi Terme
Location of Contursi Terme in Italy
Italy Campania location map.svg
Red pog.svg
Contursi Terme
Contursi Terme (Campania)
Coordinates: 40°38′N15°14′E / 40.633°N 15.233°E / 40.633; 15.233
Country Italy
Region Campania
Province Salerno (SA)
Frazioni Bagni di Contursi, Pagliarini, Toppe, Piana, Monte di Pruno, Iannamici, Prato, Ponte Mefita, Saginara, San Pietro, Serroni
Government
  MayorAntonio Briscione
Area
[1]
  Total28.90 km2 (11.16 sq mi)
Elevation
250 m (820 ft)
Population
 (31 August 2007) [2]
  Total3,281
  Density110/km2 (290/sq mi)
Demonym Contursini
Time zone UTC+1 (CET)
  Summer (DST) UTC+2 (CEST)
Postal code
84024
Dialing code 0828
Patron saint Saint Donatus
Saint day7 August
Website Official website

Contursi Terme (Contursano: Cundurs) is a village and comune in the province of Salerno in the Campania region of south-western Italy.

Contents

Early history

No secure identification of Contursi Terme, where ancient remains confirm a settlement at the confluence of the Tanagro (ancient Tanager) with the Sele, is likely. The Roman Ursentum noted in Pliny's Natural History (III.2), is more usually identified with Caggiano. [3] The local historian A. Filomarino, [4] based on etymologies of toponyms, placed the commune's origins as early as the fourth century AD, the result of efforts by the inhabitants of the former Saginara and Contursi to fortify a site that was destroyed by Alaric's Goths at the end of the fourth century. Under the Lombards it appears to have belonged to the gastaldate of Conza, [5] when a fortress was built in 840 by Orso, count of Conza, from whom the stronghold probably took its name Castrum comitis Ursi, the "castle of count Orso") [6] Orso took the part of his kinsman Siconulf of Salerno (839-51) in internecine wars with Radelchis I of Benevento, who had been a former gastaldo of Conza.

The later history of Contursi Termi [7] formed a local part of the Principality of Salerno, which was retained as a title until the territory was divided in three by Charles II of Naples in 1287, Contursi passing to the prince of Citerione (or Citra) and held by the family Sanseverino. In 1348, Contursi was taken by Louis of Taranto, king of Naples by right of his wife Joanna; he passed the title to his adherents, the Origlia. In 1448 Antonio Sanseverino succeeded in reclaiming title to Contursi, but the Sanseverino heirs held it only until the early sixteenth century, under the Viceroys of Naples. From the seventeenth century the commune passed successively through a number of families, the Bernalli, Pepe, Ludovisi and Parisani Bonanno. The last to hold the contado before the reunification of Italy were the Pisani di Tolentino, marchesi di Caggiano.

The thermal springs

The thermal baths, insecurely linked to notices by Roman writers, were described in a manuscript Balnea Contursi of 1231; [8] The fifteen thermal springs, with varying mineral content, have retained their curative reputation, for bathing, both in warm pools and in a cold plunge, and for drinking.

Parkinson's disease

Families from the village have played an important role in the understanding of Parkinson's disease. In 1986, Larry Golbe, a doctor based at the University of Medicine and Dentistry of New Jersey, came across a family with six Parkinson's patients, and found that they had originated in Contursi. [9] A few months later he found a second family with several Parkinson's patients, who also had ancestors from the village. [9] This prompted Golbe to collaborate with Giuseppe DiIorio at the University of Naples, to analyse the DNA from Contursani and people who had emigrated from the village across the world. [9] They identified three families in Italy and three families in the US, all of whom were descendants from a single couple who lived in Contursi in the late 17th and early 18th centuries. [9] Of 400 members of this extended family, known as the "Contursi kindred", 61 are known to have had Parkinson's. [9] This showed for the first time that Parkinson's could be inherited. [10]

Geneticists Alice Lazzarini and William Johnson worked through the early 1990s trying to isolate the mutation that caused the disease. [9] In 1996, a team led by Mihael Polymeropoulos at the National Institutes of Health located by linkage analysis the Parkinson's disease gene of the Contursi kindred on the long arm of human chromosome 4. [11] In 1997, the same team identified a point mutation in the alpha-synuclein gene in the Contursi kindred as well as Greek pedigrees with Parkinson's disease. [12] [13] The NIH team and a team led by Maria Grazia Spillantini reported on alpha-synuclein deposits in Lewy bodies as well as alpha-synuclein inclusions in other neurodegenerative disorders. [14] [15]

Related Research Articles

<span class="mw-page-title-main">Dementia with Lewy bodies</span> Type of progressive dementia

Dementia with Lewy bodies (DLB) is a type of dementia characterized by changes in sleep, behavior, cognition, movement, and regulation of automatic bodily functions. Memory loss is not always an early symptom. The disease worsens over time and is usually diagnosed when cognitive impairment interferes with normal daily functioning. Together with Parkinson's disease dementia, DLB is one of the two Lewy body dementias. It is a common form of dementia, but the prevalence is not known accurately and many diagnoses are missed. The disease was first described on autopsy by Kenji Kosaka in 1976, and he named the condition several years later.

<span class="mw-page-title-main">Lewy body</span> Spherical inclusion commonly found in damaged neurons

Lewy bodies are the inclusion bodies – abnormal aggregations of protein – that develop inside neurons affected by Parkinson's disease (PD), the Lewy body dementias, and some other disorders. They are also seen in cases of multiple system atrophy, particularly the parkinsonian variant (MSA-P).

<span class="mw-page-title-main">Alpha-synuclein</span> Protein found in humans

Alpha-synuclein (aSyn) is a protein that, in humans, is encoded by the SNCA gene. Alpha-synuclein is a neuronal protein that regulates synaptic vesicle trafficking and subsequent neurotransmitter release.

<span class="mw-page-title-main">Multiple system atrophy</span> Neurodegenerative disorder

Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterized by tremors, slow movement, muscle rigidity, postural instability, autonomic dysfunction and ataxia. This is caused by progressive degeneration of neurons in several parts of the brain including the basal ganglia, inferior olivary nucleus, and cerebellum.

<span class="mw-page-title-main">Ubiquitin carboxy-terminal hydrolase L1</span> Protein-coding gene in the species Homo sapiens

Ubiquitin carboxy-terminal hydrolase L1 is a deubiquitinating enzyme.

<span class="mw-page-title-main">Neurodegenerative disease</span> Central nervous system disease

A neurodegenerative disease is caused by the progressive loss of neurons, in the process known as neurodegeneration. Neuronal damage may also ultimately result in their death. Neurodegenerative diseases include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, tauopathies, and prion diseases. Neurodegeneration can be found in the brain at many different levels of neuronal circuitry, ranging from molecular to systemic.Because there is no known way to reverse the progressive degeneration of neurons, these diseases are considered to be incurable; however research has shown that the two major contributing factors to neurodegeneration are oxidative stress and inflammation. Biomedical research has revealed many similarities between these diseases at the subcellular level, including atypical protein assemblies and induced cell death. These similarities suggest that therapeutic advances against one neurodegenerative disease might ameliorate other diseases as well.

Synucleins are a family of soluble proteins common to vertebrates, primarily expressed in neural tissue and in certain tumors.

<span class="mw-page-title-main">Beta-synuclein</span> Protein-coding gene in the species Homo sapiens

Beta-synuclein is a protein that in humans is encoded by the SNCB gene.

<span class="mw-page-title-main">Gamma-synuclein</span> Protein-coding gene in the species Homo sapiens

Gamma-synuclein is a protein that in humans is encoded by the SNCG gene.

<span class="mw-page-title-main">LRRK2</span> Protein kinase found in humans

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin and PARK8, is a large, multifunctional kinase enzyme that in humans is encoded by the LRRK2 gene. LRRK2 is a member of the leucine-rich repeat kinase family. Variants of this gene are associated with an increased risk of Parkinson's disease and Crohn's disease.

<span class="mw-page-title-main">Collagen, type X, alpha 1</span> Protein found in humans

Collagen alpha-1(X) chain is a protein that in humans is a member of the collagen family encoded by the COL10A1 gene.

<span class="mw-page-title-main">SNCAIP</span> Protein-coding gene in the species Homo sapiens

Synphilin-1 is a protein that in humans is encoded by the SNCAIP gene. SNCAIP stands for "synuclein, alpha interacting protein" and can be signified by SNCAP_HUMAN, synphilin 1, synuclein, alpha interacting protein (synphilin), and SYPH1.

<span class="mw-page-title-main">Parkinson's disease</span> Long-term neurodegenerative disease

Parkinson's disease (PD), or simply Parkinson's, is a neurodegenerative disease of mainly the central nervous system that affects both the motor and non-motor systems of the body. The symptoms usually emerge slowly, and, as the disease progresses, non-motor symptoms become more common. Usual symptoms include tremors, slowness of movement, rigidity, and difficulty with balance, collectively known as parkinsonism. Parkinson's disease dementia, falls and neuropsychiatric problems such as sleep abnormalities, psychosis, mood swings, or behavioral changes may also arise in advanced stages.

<span class="mw-page-title-main">History of Parkinson's disease</span>

The history of Parkinson's disease expands from 1817, when British apothecary James Parkinson published An Essay on the Shaking Palsy, to modern times. Before Parkinson's descriptions, others had already described features of the disease that would bear his name, while the 20th century greatly improved knowledge of the disease and its treatments. PD was then known as paralysis agitans. The term "Parkinson's disease" was coined in 1865 by William Sanders and later popularized by French neurologist Jean-Martin Charcot.

Parkinson's disease (PD) is a complicated neurodegenerative disease that progresses over time and is marked by bradykinesia, tremor, and stiffness. As the condition worsens, some patients may also experience postural instability. Parkinson's disease (PD) is primarily caused by the gradual degeneration of dopaminergic neurons in the region known as the substantia nigra along with other monoaminergic cell groups throughout the brainstem, increased activation of microglia, and the build-up of Lewy bodies and Lewy neurites, which are proteins found in surviving dopaminergic neurons.

Maria Grazia Spillantini is Professor of Molecular Neurology in the Department of Clinical Neurosciences at the University of Cambridge. She is most noted for identifying the protein alpha-synuclein as the major component of Lewy bodies, the characteristic protein deposit found in the brain in Parkinson's disease and dementia with Lewy bodies. She has also identified mutations in the MAPT gene as a heritable cause for frontotemporal dementia.

<span class="mw-page-title-main">Alice Lazzarini</span> Scientist, author and researcher

Alice M. Lazzarini is a scientist, author and researcher on neurogenetic disorders, including Huntington's disease and Parkinson's disease. She is an assistant professor of Neurology at Rutgers Robert Wood Johnson Medical School, where her work helped establish the genetic basis of Parkinson's. Later in life, she was diagnosed with Parkinson's—the very disease she had spent decades researching.

<span class="mw-page-title-main">Synucleinopathy</span> Medical condition

Synucleinopathies are neurodegenerative diseases characterised by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells. There are three main types of synucleinopathy: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Other rare disorders, such as various neuroaxonal dystrophies, also have α-synuclein pathologies. Additionally, autopsy studies have shown that around 6% of sporadic Alzheimer's Disease exhibit α-synuclein positive Lewy pathology, and are sub-classed as Alzheimer's Disease with Amygdalar Restricted Lewy Bodies (AD/ALB).

<span class="mw-page-title-main">Proprotein convertase subtilisin/kexin type 1 inhibitor</span> Mammalian protein found in Homo sapiens

Proprotein convertase subtilisin/kexin type 1 inhibitor is a protein by the name of proSAAS that in humans is encoded by the PCSK1N gene.

The Parkinson's Foundation is a national organization that funds research and provides educational resources to Parkinson's disease patients and caregivers. The Parkinson's Foundation was established in 2016 through the merger of the National Parkinson Foundation and the Parkinson's Disease Foundation. The Parkinson's Foundation has headquarters in Miami and New York City, in addition to 17 chapters throughout the United States.

References

  1. "Superficie di Comuni Province e Regioni italiane al 9 ottobre 2011". Italian National Institute of Statistics. Retrieved 16 March 2019.
  2. All demographics and other statistics: Italian statistical institute ISTAT
  3. Megale Hellas: Glossario dei Toponomastica Antica
  4. Filomarino, Contursi figlia di Saginara Rome, 1923.
  5. Franco Pignata "Il Sentiero dei passi perduti"
  6. Vito Lembo, op.cit.
  7. The history is taken from Storia delle Termi and from Vito Lembo, historical notes in Per la Campania, December 1905 (on-line text).
  8. The manuscript is conserved in the Archivio della Badia della SS. Trinità di Cava dei Tirreni (Storia delle termi).
  9. 1 2 3 4 5 6 Jacobs, Eve (2004). "Gene Hunter". UMDNJ Magazine. University of Medicine and Dentistry of New Jersey. Archived from the original on June 6, 2013. Retrieved December 9, 2013.
  10. Golbe, LI; Di Iorio, G; Bonavita, V; Miller, DC; Duvoisin, RC; et al. (1990), "A large kindred with autosomal dominant Parkinson's disease", Ann Neurol., vol. 27, no. 3, pp. 276–82, doi:10.1002/ana.410270309, PMID   2158268, S2CID   31767548
  11. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al. (1996). "Mapping of a gene for Parkinson's disease to chromosome 4q21-q23". Science. 274 (5290): 1197–9. doi:10.1126/science.274.5290.1197. PMID   8895469. S2CID   25330514.
  12. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. (1997). "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease". Science. 276 (5321): 2045–7. doi:10.1126/science.276.5321.2045. PMID   9197268.
  13. Polymeropoulos MH (2000). "Genetics of Parkinson's disease". Ann N Y Acad Sci. 920: 28–32. CiteSeerX   10.1.1.554.6455 . doi:10.1111/j.1749-6632.2000.tb06901.x. PMID   11193165. S2CID   21926190.
  14. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ (1998). "Alpha synuclein in neurodegenerative disorders: murderer or accomplice?". Nat Med. 4 (7): 755–7. doi:10.1038/nm0798-755. PMID   9662355. S2CID   46196799.
  15. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997). "Alpha-synuclein in Lewy bodies". Nature. 388 (6645): 839–40. doi: 10.1038/42166 . PMID   9278044.